{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "CAIRO4 is a randomized phase 3 trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "patients with mCRC were randomized to systemic treatment only or PTR followed by systemic treatment"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients included between August 2012 and December 2019 with histologically proven colorectal cancer, unresectable metastases, and a primary tumor with few or absent symptoms were eligible."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Systemic treatment, consisting of fluoropyrimidine-based chemotherapy with bevacizumab vs PTR followed by fluoropyrimidine-based chemotherapy with bevacizumab."
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective: To determine the difference in 60-day mortality between patients randomized to systemic treatment only vs PTR followed by systemic treatment, and to explore risk factors associated with 60-day mortality."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The aim of the current analysis was to compare 60-day mortality rates in both treatment arms."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Patients included between August 2012 and December 2019"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "A total of 196 patients were included in the intention-to-treat analysis"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Sixty-day mortality was 3% (95% CI, 1%-9%) in the systemic treatment arm and 11% (95% CI, 6%-19%) in the PTR arm ( P =\u2009.03)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Patients with elevated serum levels of lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, and/or neutrophils who were randomized to PTR had a significantly higher 60-day mortality than patients without these characteristics."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: ClinicalTrials.gov Identifier: NCT01606098"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}